Moeen Khan
Examiner (ID: 1439)
Most Active Art Unit | 2436 |
Art Unit(s) | 2436 |
Total Applications | 231 |
Issued Applications | 116 |
Pending Applications | 61 |
Abandoned Applications | 54 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 13622161
[patent_doc_number] => 20180362632
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-20
[patent_title] => ANTI-GM-CSF ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/100063
[patent_app_country] => US
[patent_app_date] => 2018-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19894
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100063
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/100063 | Anti-GM-CSF antibodies and uses thereof | Aug 8, 2018 | Issued |
Array
(
[id] => 14102307
[patent_doc_number] => 20190092829
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-28
[patent_title] => INHIBITION OF IL-17 PRODUCTION
[patent_app_type] => utility
[patent_app_number] => 15/957879
[patent_app_country] => US
[patent_app_date] => 2018-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13865
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15957879
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/957879 | INHIBITION OF IL-17 PRODUCTION | Apr 18, 2018 | Abandoned |
Array
(
[id] => 13476565
[patent_doc_number] => 20180289825
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-11
[patent_title] => Single Chain Fc Fusion Proteins
[patent_app_type] => utility
[patent_app_number] => 15/949596
[patent_app_country] => US
[patent_app_date] => 2018-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18104
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15949596
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/949596 | Single chain Fc fusion proteins | Apr 9, 2018 | Issued |
Array
(
[id] => 16756619
[patent_doc_number] => 10975157
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-13
[patent_title] => Anti-OX40 antibodies and diagnostic uses thereof
[patent_app_type] => utility
[patent_app_number] => 15/921254
[patent_app_country] => US
[patent_app_date] => 2018-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 14841
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15921254
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/921254 | Anti-OX40 antibodies and diagnostic uses thereof | Mar 13, 2018 | Issued |
Array
(
[id] => 13386443
[patent_doc_number] => 20180244763
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-30
[patent_title] => ANTI-TGF-BETA ANTIBODIES AND THEIR USE
[patent_app_type] => utility
[patent_app_number] => 15/875532
[patent_app_country] => US
[patent_app_date] => 2018-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19232
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15875532
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/875532 | Anti-TGF-b antibodies and their use | Jan 18, 2018 | Issued |
Array
(
[id] => 12794947
[patent_doc_number] => 20180156818
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-07
[patent_title] => METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 15/858661
[patent_app_country] => US
[patent_app_date] => 2017-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27722
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15858661
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/858661 | METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE | Dec 28, 2017 | Abandoned |
Array
(
[id] => 13331245
[patent_doc_number] => 20180217160
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-02
[patent_title] => IL1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target
[patent_app_type] => utility
[patent_app_number] => 15/849135
[patent_app_country] => US
[patent_app_date] => 2017-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32030
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849135
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/849135 | IL1RL-1 as a cardiovascular disease marker and therapeutic target | Dec 19, 2017 | Issued |
Array
(
[id] => 12794962
[patent_doc_number] => 20180156823
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-07
[patent_title] => METHODS OF DETERMINING RISK OF CARDIAC ARRHYTHMIA
[patent_app_type] => utility
[patent_app_number] => 15/830886
[patent_app_country] => US
[patent_app_date] => 2017-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25220
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15830886
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/830886 | METHODS OF DETERMINING RISK OF CARDIAC ARRHYTHMIA | Dec 3, 2017 | Abandoned |
Array
(
[id] => 12157356
[patent_doc_number] => 20180028621
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-02-01
[patent_title] => 'METHODS OF INDUCING INDOLAMINE 2,3 - DIOXYGENASE (IDO)'
[patent_app_type] => utility
[patent_app_number] => 15/785075
[patent_app_country] => US
[patent_app_date] => 2017-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 9957
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15785075
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/785075 | METHODS OF INDUCING INDOLAMINE 2,3 - DIOXYGENASE (IDO) | Oct 15, 2017 | Abandoned |
Array
(
[id] => 12178711
[patent_doc_number] => 20180037647
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-02-08
[patent_title] => 'Cachexia Treatment'
[patent_app_type] => utility
[patent_app_number] => 15/730218
[patent_app_country] => US
[patent_app_date] => 2017-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 5742
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15730218
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/730218 | Cachexia treatment | Oct 10, 2017 | Issued |
Array
(
[id] => 13399921
[patent_doc_number] => 20180251503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-06
[patent_title] => MULTIMERIZATION TECHNOLOGIES
[patent_app_type] => utility
[patent_app_number] => 15/715499
[patent_app_country] => US
[patent_app_date] => 2017-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20888
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15715499
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/715499 | MULTIMERIZATION TECHNOLOGIES | Sep 25, 2017 | Abandoned |
Array
(
[id] => 15882871
[patent_doc_number] => 10647767
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-05-12
[patent_title] => Anti-GM-CSF antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 15/744734
[patent_app_country] => US
[patent_app_date] => 2017-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 12
[patent_no_of_words] => 19981
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15744734
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/744734 | Anti-GM-CSF antibodies and uses thereof | Sep 17, 2017 | Issued |
Array
(
[id] => 15225099
[patent_doc_number] => 10500254
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-12-10
[patent_title] => Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
[patent_app_type] => utility
[patent_app_number] => 15/695587
[patent_app_country] => US
[patent_app_date] => 2017-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 6199
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 286
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15695587
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/695587 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen | Sep 4, 2017 | Issued |
Array
(
[id] => 16215138
[patent_doc_number] => 10730936
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-08-04
[patent_title] => Engineered anti-TGF-b antibodies and antigen-binding fragments
[patent_app_type] => utility
[patent_app_number] => 15/670631
[patent_app_country] => US
[patent_app_date] => 2017-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 14224
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15670631
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/670631 | Engineered anti-TGF-b antibodies and antigen-binding fragments | Aug 6, 2017 | Issued |
Array
(
[id] => 11993987
[patent_doc_number] => 20170298142
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-19
[patent_title] => 'ANTIBODIES TO TIP-1 AND GRP78'
[patent_app_type] => utility
[patent_app_number] => 15/628209
[patent_app_country] => US
[patent_app_date] => 2017-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 47
[patent_figures_cnt] => 47
[patent_no_of_words] => 17533
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15628209
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/628209 | Antibodies to GRP78 | Jun 19, 2017 | Issued |
Array
(
[id] => 12657013
[patent_doc_number] => 20180110837
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-26
[patent_title] => METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION
[patent_app_type] => utility
[patent_app_number] => 15/621062
[patent_app_country] => US
[patent_app_date] => 2017-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30643
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15621062
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/621062 | METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION | Jun 12, 2017 | Abandoned |
Array
(
[id] => 12118850
[patent_doc_number] => 20180002436
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-04
[patent_title] => 'TARGETED TGFß INHIBITION'
[patent_app_type] => utility
[patent_app_number] => 15/617876
[patent_app_country] => US
[patent_app_date] => 2017-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 22905
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15617876
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/617876 | TARGETED TGFß INHIBITION | Jun 7, 2017 | Abandoned |
Array
(
[id] => 11971201
[patent_doc_number] => 20170275354
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-28
[patent_title] => 'ANTIBODIES TO M-CSF'
[patent_app_type] => utility
[patent_app_number] => 15/614237
[patent_app_country] => US
[patent_app_date] => 2017-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 39529
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15614237
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/614237 | Antibodies to M-CSF | Jun 4, 2017 | Issued |
Array
(
[id] => 12150101
[patent_doc_number] => 20180021365
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-25
[patent_title] => 'ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS'
[patent_app_type] => utility
[patent_app_number] => 15/611722
[patent_app_country] => US
[patent_app_date] => 2017-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 37729
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15611722
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/611722 | ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS | May 31, 2017 | Abandoned |
Array
(
[id] => 11963633
[patent_doc_number] => 20170267784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-21
[patent_title] => 'SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS'
[patent_app_type] => utility
[patent_app_number] => 15/608255
[patent_app_country] => US
[patent_app_date] => 2017-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 37940
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608255
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/608255 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS | May 29, 2017 | Abandoned |